Notably, BKT300 was effective across various cell lines with a range of mutations, including TP53, FLT3-ITD, NRAS, PTEN, and KMT2A, underscoring its broad therapeutic potential in targeting diverse genetic alterations in AML. Here, TP53 is linked to acute myeloid leukemia.